Navigation Links
Environmental Tectonics Corporation Announces Sale of Additional Monoplace Hyperbaric Chambers

SOUTHAMPTON, Pa., July 14 /PRNewswire-FirstCall/ -- Environmental Tectonics Corporation's (OTC Bulletin Board: ETCC) ("ETC" or the "Company") BioMedical Systems Division has contracted with Life Support Technologies (LST), a wound care management group located in Mt. Vernon, NY, for delivery and installation of two BARA-MED((R)) XD monoplace hyperbaric chambers in Hudson Valley Hospital, Cortlandt Manor, NY.

To date LST has purchased from ETC and operates over twenty (20) of the BARA-MED((R)) series of hyperbaric chambers. LST is the recognized expert in hyperbaric medicine, chronic wound treatment, and clinical business management operating in the New York Tri-State area. They are also a NASA and U.S. Military Hyper/Hypobaric contractor known for their work in underwater zero-G neutral buoyancy astronaut training and high altitude simulation systems.

Glenn Butler, President & CEO of Life Support Technologies, commented, "We utilize ETC BARA-MED((R) )monoplace hyperbaric chambers exclusively due to their advanced engineering, low oxygen consumption and Electronic Medical Record (EMR) compatibility."

All monoplace hyperbaric chambers designed and manufactured by ETC BioMedical are automated with O.S.C.A.R.( )(TM), (Operating System for Control And Recordkeeping). O.S.C.A.R.( )(TM) is a computerized operating system that includes a patient friendly pressurization alternative (Smooth Ride(TM)) that minimizes complications due to middle ear and sinus barotraumas without increasing compression time, programmable treatment protocols and more. As an added safety feature, ETC's chambers feature a full manual override system to avoid premature termination of treatment protocol as a result of power outages.

ETC's Biomedical Division has been providing state of the art chambers for Hyperbaric Oxygen Therapy (HBOT) since 1987 and continues to be the only manufacturer of a time-proven computerized monoplace hyperbaric chamber.

Bob Salmons, NE Regional Manager of ETC's BioMedical Division, commented, "We value our continued working relationship with Life Support Technologies. They represent one of the many satisfied customers who understand the versatility and unique applicability of ETC's state of the art technology."

ETC was incorporated in 1969 in Pennsylvania and this year we will celebrate our 40(th) anniversary. Our core technologies include the design, manufacture and sale of Training Services (TSG) which includes (1) software driven products and services used to create and monitor the physiological effects of flight; (2) high performance jet tactical flight simulation, and; (3) driving and disaster simulation systems, and Control Systems (CSG) which includes: (1) steam and gas sterilization; (2) testing and simulation devices for the automotive industry, and; (3) hyperbaric and hypobaric chambers. Product categories included in TSG are Aircrew Training Systems (ATS) and flight simulators, disaster management systems and entertainment applications. CSG includes sterilizers, environmental control devices and hyperbaric chambers along with parts and service support.

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based on ETC's current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about ETC and its subsidiaries that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

These forward-looking statements include statements with respect to the Company's vision, mission, strategies, goals, beliefs, plans, objectives, expectations, anticipations, estimates, intentions, financial condition, results of operations, future performance and business of the company, including but not limited to, (i) potential additional funding by H.F. Lenfest, a member of our Board of Directors and a significant shareholder, and PNC Bank, (ii) the trading of the Company's common stock on the Over-the-Counter Bulletin Board (iii) projections of revenues, costs of materials, income or loss, earnings or loss per share, capital expenditures, growth prospects, dividends, capital structure, other financial items and the effects of currency fluctuations, (iv) statements of our plans and objectives of the Company or its management or Board of Directors, including the introduction of new products, or estimates or predictions of actions of customers, suppliers, competitors or regulatory authorities, (v) statements of future economic performance, (vi) statements of assumptions and other statements about the Company or its business, (vii) statements made about the possible outcomes of litigation involving the Company, (viii) statements regarding the Company's ability to obtain financing to support its operations and other expenses, and (ix) statements preceded by, followed by or that include the words, "may," "could," "should," "looking forward," "would," "believe," "expect," "anticipate," "estimate," "intend," "plan," or the negative of such terms or similar expressions. These forward-looking statements involve risks and uncertainties which are subject to change based on various important factors. Some of these risks and uncertainties, in whole or in part, are beyond the Company's control. Factors that might cause or contribute to such a material difference include, but are not limited to, those discussed in the Company's Annual Report on Form 10K for the fiscal year ended February 27, 2009, in the section entitled "Risks Particular to Our Business." Shareholders are urged to review these risks carefully prior to making an investment in the Company's common stock.

The Company cautions that the foregoing list of important factors is not exclusive. Except as required by federal securities law, the Company does not undertake to update any forward-looking statement, whether written or oral, that may be made from time to time by or on behalf of the Company.

    Contact: Duane D. Deaner, CFO Tel: 215-355-9100 (ext. 1203)
                                  Fax: 215-357-4000
    ETC - Internet Home Page

SOURCE Environmental Tectonics Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Bion Announces Approval of New U.S. Patent that Broadens Protection for the Companys Livestock Waste Environmental Treatment Processes
2. Environmental Tectonics Corporations BioMedical Division to Exhibit at Undersea and Hyperbaric Medical Society Meeting
3. Environmental Tectonics Corporations BioMedical Division Achieves Foreign Manufacturer Accreditation in Japan
4. Environmental Tectonics Corporation Announces Additional Hyperbaric Monoplace Chamber Sale to St. John Wound Center
5. Springborn Deploys eStudy(TM) Hosted Solution for Management of Global Environmental Testing
6. Research Reinforces Economic, Environmental Benefits of Corn Cobs as Source for Cellulosic Ethanol
7. Environmental Tectonics Corporation Expands BioMedical Systems Division Sales Staff
8. Opus Environmental Introduces Innovative Food Waste Elimination Equipment to U.S. Food Industry
9. Former EPA official calls for new environmental and consumer protection agency
10. Environmental Tectonics Corporation Exhibiting at the Annual Symposium on Advanced Wound Care and Wound Healing Society
11. ArunA Biomedical Submits Contract Proposal to Further Develop Environmental Biosensor for National Security
Post Your Comments:
(Date:11/24/2015)... /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: ... Pierre Laurin , President and Chief Executive Officer of ProMetic, ... Jaffray 27 th Annual Healthcare Conference to be held ... st , at 8.50am (ET) and ProMetic,s ... day. The presentation will be available live via a webcast ...
(Date:11/24/2015)... and NEW YORK , November ... irst investment by Bristol-Myers Squibb in a European ... Bristol-Myers Squibb Company in which the companies will ... in immuno-oncology and other areas of unmet medical need. The ... in LSP 5, the latest LSP fund. This is the ...
(Date:11/23/2015)... OAKS, Calif., Nov. 23, 2015   Ceres, Inc ... announced today financial results for the fiscal year ended ... business. --> --> ... commercializing forage and feed products with a better balance ... company signed distribution agreements with several leading crop input ...
(Date:11/23/2015)... -- The royalty-free a greement a ... daclatasvir for 112 low- and m iddle-i ... --> The Medicines Patent Pool (MPP) today ... an agreement with Bristol-Myers Squibb for daclatasvir, a novel direct-acting ... the HCV virus.  The royalty-free licence will enable generic manufacture ...
Breaking Biology Technology:
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/12/2015)... , Nov. 11, 2015   Growing need ... analytical tools has been paving the way for ... determination of discrete analytes in clinical, agricultural, environmental, ... being predominantly used in medical applications, however, their ... sectors due to continuous emphasis on improving product ...
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
Breaking Biology News(10 mins):